Lycia Therapeutics Stock (NASDAQ:LYCA)
Previous Close
$26.11
52W Range
$22.19 - $36.49
50D Avg
$27.50
200D Avg
$27.50
Market Cap
$1.30B
Avg Vol (3M)
$1.03M
Beta
-
Div Yield
-
LYCA Company Profile
Lycia Therapeutics, Inc. operates as a clinical-stage biotechnology company. It engages in the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus on addressing autoimmune, inflammatory, and allergic diseases. The company was founded in 2019 and is headquartered in South San Francisco, CA.